The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Infliximab versus vedolizumab for ICI colitis: a randomized clinical trial overview
Yinghong Wang, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a randomized clinical trial (NCT04407247) comparing infliximab and vedolizumab for immune checkpoint inhibitor (ICI) colitis. The trial explores how these treatments, targeting different pathways, affect colitis symptoms, treatment efficacy, and patient outcomes. Current treatments often involve immunosuppressants, which can lead to immune-related adverse events (irAEs), complicating cancer therapy. This interview took place during the 2024 ASCO Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MIMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role – BioNTech; Ilya Pharma; IOTA Pharmaceuticals; Janssen; Kanvas Biosciences; Mallinckrodt; Sorriso Pharmaceuticals
Patents, Royalties, Other Intellectual Property – Springer
